- Home
- GOSS vs RIGL Comparison
GOSS vs RIGL Comparison
Compare GOSS & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- RIGL
- Stock Information
- Founded
- GOSS 2015
- RIGL 1996
- Country
- GOSS United States
- RIGL United States
- Employees
- GOSS N/A
- RIGL N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- GOSS Health Care
- RIGL Health Care
- Exchange
- GOSS Nasdaq
- RIGL Nasdaq
- Market Cap
- GOSS 246.6M
- RIGL 291.9M
- IPO Year
- GOSS 2019
- RIGL 2000
- Fundamental
- Price
- GOSS $1.07
- RIGL $16.04
- Analyst Decision
- GOSS Strong Buy
- RIGL Buy
- Analyst Count
- GOSS 5
- RIGL 4
- Target Price
- GOSS $9.20
- RIGL $31.13
- AVG Volume (30 Days)
- GOSS 969.4K
- RIGL 222.4K
- Earning Date
- GOSS 11-07-2024
- RIGL 11-05-2024
- Dividend Yield
- GOSS N/A
- RIGL N/A
- EPS Growth
- GOSS N/A
- RIGL N/A
- EPS
- GOSS N/A
- RIGL N/A
- Revenue
- GOSS $95,842,000.00
- RIGL $130,201,000.00
- Revenue This Year
- GOSS N/A
- RIGL $38.26
- Revenue Next Year
- GOSS N/A
- RIGL $24.21
- P/E Ratio
- GOSS N/A
- RIGL N/A
- Revenue Growth
- GOSS N/A
- RIGL 7.48
- 52 Week Low
- GOSS $0.45
- RIGL $7.10
- 52 Week High
- GOSS $1.60
- RIGL $17.30
- Technical
- Relative Strength Index (RSI)
- GOSS 62.64
- RIGL 66.62
- Support Level
- GOSS $0.98
- RIGL $15.51
- Resistance Level
- GOSS $1.07
- RIGL $16.85
- Average True Range (ATR)
- GOSS 0.07
- RIGL 0.89
- MACD
- GOSS 0.01
- RIGL 0.07
- Stochastic Oscillator
- GOSS 83.26
- RIGL 70.08
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.